Chlorthalidone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00310 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 26 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary hereditary glaucoma | KG + DL |
| 2 | open-angle glaucoma | KG + DL |
| 3 | malignant renovascular hypertension | KG + DL |
| 4 | malignant hypertensive renal disease | KG + DL |
| 5 | pulmonary hypertension owing to lung disease and/or hypoxia | KG + DL |
| 6 | pulmonary hypertension with unclear multifactorial mechanism | KG + DL |
| 7 | Braddock syndrome | KG + DL |
| 8 | chronic pulmonary heart disease | KG + DL |
| 9 | acute pulmonary heart disease | KG + DL |
| 10 | congenital hypotrichosis milia | KG + DL |
| 11 | hypotrichosis simplex of the scalp | KG + DL |
| 12 | diffuse alopecia areata | KG + DL |
| 13 | glaucoma 1, open angle | KG + DL |
| 14 | alopecia | KG + DL |
| 15 | respiratory failure | KG + DL |
| 16 | hypertrophic cardiomyopathy | KG + DL |
| 17 | hypertrophic cardiomyopathy due to intensive athletic training | KG + DL |
| 18 | distal myopathy, Tateyama type | KG + DL |
| 19 | open angle glaucoma | KG + DL |
| 20 | congenital myopathy with excess of thin filaments | KG + DL |
| 21 | closed-angle glaucoma | KG + DL |
| 22 | cirrhotic cardiomyopathy | KG + DL |
| 23 | phosphoenolpyruvate carboxykinase deficiency | KG + DL |
| 24 | phosphoenolpyruvate carboxykinase deficiency, cytosolic | KG + DL |
| 25 | borderline glaucoma | KG + DL |
| 26 | cardiomyopathy | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.